VAXXINITY INC-A (VAXX) Forecast, Price Target & Analyst Ratings

NASDAQ:VAXX • US92244V1044

Current stock price

0.1111 USD
-0.02 (-15.26%)
At close:
0.1107 USD
0 (-0.36%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VAXXINITY INC-A (VAXX).

Forecast Snapshot

Consensus Price Target

Price Target
$15.30
+ 13,671.38% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Aug 7, 2024
Period
Q1 / 2024
EPS Estimate
-$0.10
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
87.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$15.30
Upside
+ 13,671.38%
From current price of $0.11 to mean target of $15.30, Based on 8 analyst forecasts
Low
$15.15
Median
$15.30
High
$15.75

Price Target Revisions

1 Month
0.00%
3 Months
36.36%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for VAXX. The average price target is 15.3 USD. This implies a price increase of 13671.38% is expected in the next year compared to the current price of 0.1111.
The average price target has been revised upward by 36.36% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

VAXX Current Analyst RatingVAXX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

VAXX Historical Analyst RatingsVAXX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
87.50%
VAXX was analyzed by 8 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about VAXX.
In the previous month the buy percentage consensus was at a similar level.
VAXX was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-09-08BairdInitiate Outperform
2022-04-27Evercore ISI GroupInitiate In-Line
2021-12-07JefferiesInitiate Buy
2021-12-06B of A SecuritiesInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Aug 7, 2024
Period
Q1 / 2024
EPS Estimate
-$0.10
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
32.00%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

VAXX is expected to report earnings on 8/7/2024. The consensus EPS estimate for the next earnings is -0.1 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2024 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
VAXX revenue by date.VAXX revenue by date.
560K70K
-87.50%
-100.00%		31.671M40.698M
28.50%		74.763M
83.70%		145.97M
95.24%		234.72M
60.80%
EBITDA
YoY % growth
VAXX ebitda by date.VAXX ebitda by date.
-13.55M-31.56M
-132.92%		-123.98M
-292.84%		-76.612M
40.07%		-95.217M
24.56%		-108.946M
-94.37%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
VAXX ebit by date.VAXX ebit by date.
-13.66M-32.28M
-136.31%		-125.08M
-287.48%		-77.459M
39.25%		-61.191M
23.29%		-52.962M
9.13%		-60.907M
-15.00%		-59.451M
2.39%		-49.555M
16.65%		-27.418M
44.67%		37.391M
236.37%		120.22M
221.52%
Operating Margin
VAXX operating margin by date.VAXX operating margin by date.
N/A-5,764.29%-178,685.71%N/AN/AN/AN/A-187.71%-121.76%-36.67%25.62%51.22%
EPS
YoY % growth
VAXX eps by date.VAXX eps by date.
N/AN/AN/A-0.61
62.05%		-0.47
21.80%		-0.39
17.39%		-0.40
-2.63%		-0.42
-5.13%		-0.42-0.39
7.32%		-0.33
15.79%		-0.27
18.75%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.10
32.00%		-0.10
7.27%		-0.10
-2.00%		-0.08
20.00%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-13.441M
28.55%		-13.307M
7.78%		-13.173M
2.06%		-13.042M
-11.95%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

VAXX Yearly Revenue VS EstimatesVAXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2026 2027 2028 2029 2030 50M 100M 150M 200M
VAXX Yearly EPS VS EstimatesVAXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
3.50%
EPS Next 5 Year
3.26%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

VAXXINITY INC-A / VAXX Forecast FAQ

What do analysts expect the price target to be for VAXXINITY INC-A (VAXX)?

8 analysts have analysed VAXX and the average price target is 15.3 USD. This implies a price increase of 13671.38% is expected in the next year compared to the current price of 0.1111.

When does VAXXINITY INC-A (VAXX) report earnings?

VAXXINITY INC-A (VAXX) will report earnings on 2024-08-07, after the market close.

Can you provide the consensus estimates for VAXXINITY INC-A next earnings?

The consensus EPS estimate for the next earnings of VAXXINITY INC-A (VAXX) is -0.1 USD and the consensus revenue estimate is 0 USD.

What is the number of analysts for VAXX stock?

The number of analysts covering VAXXINITY INC-A (VAXX) is 8.